[go: up one dir, main page]

HUP0500921A2 - Tetrazole derivatives, process for their preparation and their use - Google Patents

Tetrazole derivatives, process for their preparation and their use

Info

Publication number
HUP0500921A2
HUP0500921A2 HU0500921A HUP0500921A HUP0500921A2 HU P0500921 A2 HUP0500921 A2 HU P0500921A2 HU 0500921 A HU0500921 A HU 0500921A HU P0500921 A HUP0500921 A HU P0500921A HU P0500921 A2 HUP0500921 A2 HU P0500921A2
Authority
HU
Hungary
Prior art keywords
preparation
tetrazole derivatives
tetrazole
derivatives
Prior art date
Application number
HU0500921A
Other languages
Hungarian (hu)
Inventor
Krisztina Dr Gal
Csaba Weber
Gabor Andras Wagner
Amrita Agnes Bobok
Gyoergyne Dr Nyeki
Monika Dr Vastag
Gyoergy Dr Keserue
Viktor Dr Hada
Janos Koti
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Priority to HU0500921A priority Critical patent/HUP0500921A2/en
Publication of HU0500921D0 publication Critical patent/HU0500921D0/en
Priority to PCT/HU2006/000088 priority patent/WO2007039782A1/en
Publication of HUP0500921A2 publication Critical patent/HUP0500921A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU0500921A 2005-10-05 2005-10-05 Tetrazole derivatives, process for their preparation and their use HUP0500921A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HU0500921A HUP0500921A2 (en) 2005-10-05 2005-10-05 Tetrazole derivatives, process for their preparation and their use
PCT/HU2006/000088 WO2007039782A1 (en) 2005-10-05 2006-10-05 Tetrazole derivatives as modulators of metabotropic glutamate receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0500921A HUP0500921A2 (en) 2005-10-05 2005-10-05 Tetrazole derivatives, process for their preparation and their use

Publications (2)

Publication Number Publication Date
HU0500921D0 HU0500921D0 (en) 2005-12-28
HUP0500921A2 true HUP0500921A2 (en) 2007-07-30

Family

ID=89986318

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500921A HUP0500921A2 (en) 2005-10-05 2005-10-05 Tetrazole derivatives, process for their preparation and their use

Country Status (2)

Country Link
HU (1) HUP0500921A2 (en)
WO (1) WO2007039782A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200811137A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators II
TW200808777A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGLUR5 modulators III
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
US9339035B2 (en) 2010-09-02 2016-05-17 Monsanto Technology Llc Compositions and methods for controlling nematode pests
MX2013004286A (en) * 2010-10-21 2013-06-05 Bayer Ip Gmbh 1-(heterocyclic carbonyl) piperidines.
US9173401B2 (en) 2013-03-15 2015-11-03 Monsanto Technology Llc N-,C-disubstituted azoles and compositions and methods for controlling nematode pests
EP3224245B1 (en) * 2014-12-24 2018-09-12 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
WO2017002083A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
BR112022005289A2 (en) * 2019-10-17 2022-09-20 Givaudan Sa AZACICLES SUBSTITUTED AS TRMP8 MODULATORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253190B2 (en) * 2001-10-04 2007-08-07 Merck & Co., Inc. Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5
KR20070027504A (en) * 2004-02-18 2007-03-09 아스트라제네카 아베 Tetrazole Compounds and Their Uses as Metabolic Glutamate Receptor Antagonists
MXPA06009023A (en) * 2004-02-18 2007-03-08 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists.
WO2006048771A1 (en) * 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors

Also Published As

Publication number Publication date
WO2007039782A1 (en) 2007-04-12
HU0500921D0 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
EP1937766A4 (en) Modified polyamides, uses thereof and process for their preparation
PL1928882T3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
ZA200903160B (en) Sulfonyl-Phenyl-2H-[1,2,4]Oxodiazol-5-one Derivatives, Processes for their preparation and their use as pharmaceuticals
ZA200805939B (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL220816A0 (en) Process for preparing cell-binding agent-cytotoxic agent
PL1913001T3 (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
IL191655A0 (en) Novel compounds, their preparation and use
IL179424A0 (en) Substituted oxazole -benzoisothiazole dioxide derivatives, process for their preparation and their use
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
IL185484A0 (en) Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
PL1874765T3 (en) Urea derivatives, methods for their manufacture and uses thereof
PL1988090T3 (en) Imidazol-5-carboxylic acid derivatives, preparation methods and use therrof
IL187235A0 (en) 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
IL187392A0 (en) Thiazole derivatives, their preparation and use
ZA200801629B (en) Phenyl - and pyridinyl - 1, 2, 4 - oxadiozolone derivatives, processes for their preparation and their use as pharmaceuticals
IL193236A0 (en) Novel pyrone-indole derivatives and process for their preparation
IL193341A0 (en) Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
IL193339A0 (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL184314A0 (en) Substituted 4-phenyltetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
SI2020410T1 (en) PyridoŠ2,3-dĆpyrimidine derivatives, process for their preparation and their therapeutical use
PT1922309E (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
IL190596A0 (en) 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
HUP0500921A2 (en) Tetrazole derivatives, process for their preparation and their use
IL190334A0 (en) Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees